Home > Authorities > Grants > Record #880628 > print

001     880628
005     20230825115957.0
024 7 _ |a G:(EU-Grant)946589
|d 946589
|2 CORDIS
024 7 _ |a G:(EU-Call)H2020-EIC-SMEInst-2018-2020-3
|d H2020-EIC-SMEInst-2018-2020-3
|2 CORDIS
024 7 _ |a corda__h2020::946589
|2 originalID
035 _ _ |a G:(EU-Grant)946589
150 _ _ |a A safe and effective replacement valve for treating severe Tricuspid Regurgitation and preventing Right Ventricle dysfunction
|y 2020-02-01 - 2024-01-31
371 _ _ |a TRISOL MEDICAL LTD
|d Israel
|e https://www.trisol-medical.com/
|v CORDIS
372 _ _ |a H2020-EIC-SMEInst-2018-2020-3
|s 2020-02-01
|t 2024-01-31
450 _ _ |a Trisol System
|w d
|y 2020-02-01 - 2024-01-31
510 1 _ |0 I:(DE-588b)5098525-5
|a European Union
|2 CORDIS
680 _ _ |a In Europe, an estimated 6.5M people are affected by heart valve disease (HVD) each year. Tricuspid regurgitation (TR) is a HVD which occurs when the tricuspid valve fails to close properly, causing blood to flow backward into the right atrium. Many cases of TR are accompanied by Right Ventricle (RV) Dysfunction. The gold standard methods for tricuspid valve diseases are standard open-heart surgery and transcatheter valve replacement. However, high-risk interventions require long recovery time long in-hospital stays and have significant hospital mortality (more than 10%). Due to the high risk related to the surgical procedure, most of the patients cannot be treated. As such, there is a significant unmet clinical need for a transcatheter solution to TR. Trisol is introducing the Trisol System, a transcatheter tricuspid valve replacement system for treating severe TR and preventing RV dysfunction. The Trisol valve is constructed out of nitinol frame with specially designed sail-like leaflet. A flexible delivery system is used to position the valve into the heart with support arms anchoring to the tricuspid physiological site. The Trisol System allows cardiologists to perform a quick and safe implant procedure (30 minutes compared to 2-4 hours of standard surgery) thus increasing the number of treated population and reducing in-hospital and recovery time. Moreover, it will increase heart performance and reduce the risk of mortality typical of open-heart surgeries. The Phase 2 project will enable Trisol to scale-up production, perform validation and verification activities including a preclinical study; and validate the safety and efficacy of the Trisol System in the First-In-Human and CE mark clinical trial.
909 C O |o oai:juser.fz-juelich.de:880628
|p authority:GRANT
|p authority
970 _ _ |a oai:dnet:corda__h2020::3e21d8ded11a9367369c20c600d26224
980 _ _ |a G
980 _ _ |a CORDIS
980 _ _ |a AUTHORITY

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21